Saquinavir Mesylate



Saquinavir Mesylate





(sa kwen’ a veer)

Invirase

PREGNANCY CATEGORY B


Drug Classes

Antiretroviral

Protease inhibitor


Therapeutic Actions

Protease inhibitor, which in combination with nucleoside analogues is effective in HIV infections with changes in surrogate markers.


Indications



  • Treatment of HIV infection in combination with other antiretrovirals in patients older than 16 yr



Available Forms

Capsules—200 mg; tablets—500 mg


Dosages

Adults and patients older than 16 yr

1,000 mg bid with ritonavir 100 mg bid given together within 2 hr after a meal or with lopinavir 400 mg/ritonavir 100 mg PO bid (tablets); 1,000 mg bid PO with lopinavir 400 mg ritonavir 100 mg PO bid (capsules).

Pediatric patients younger than 16 yr

Safety and efficacy not established.

Patients with hepatic impairment

Drug is contraindicated with severe hepatic impairment.


Pharmacokinetics















Route Onset Peak
Oral Slow Unknown

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 21, 2016 | Posted by in NURSING | Comments Off on Saquinavir Mesylate

Full access? Get Clinical Tree

Get Clinical Tree app for offline access